iNFixion Bioscience announced today that it had been granted its second NIH Phase 1 SBIR Grant award from the National Institute of Neurological Disorders and Stroke (NINDS). This 18-month grant, titled “Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency” is focused on identifying small molecule compounds that impact the rate of intracellular NF1 protein degradation. This grant includes funding for an 18-month project that will be launched immediately, and includes continued collaboration with both the University of Wisconsin Biotechnology Center and Scripps Research in San Diego.
SIGN UP FOR THE iNFixion Bioscience
Newsletter
Receive occasional updates sharing iNFixion’s progress and other newsworthy events.
Ⓒ iNFixion Bioscience (2017-2021). All rights reserved.